Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
A new study finds that the anti-craving drug, Naltrexone
may lessen cessation-related weight gain and negative moods and women who are trying to quit smoking appear //to benefit more than men. As a first step towards individualized medicine, scientists are focusing on gender differences in nicotine...
-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
... References to Contrave16 and Contrave48 relate to combinations containing naltrexone
SR 16mg or naltrexone
SR 48mg, respectively.
Trial Design and Results of COR Phase 3 Tr...
Addiction Drug May Help Ease Fibromyalgia
... In small study, naltrexone
offered some women relief
FRIDAY, Apri...y News) -- Low doses of an inexpensive drug called naltrexone
-- already used for years to treat drug addiction ...e drugs."
Younger said he got the idea to study naltrexone
after hearing that some other doctors had success ...
Suppressing the compulsion to steal
...d randomized them to receive treatment with either naltrexone
or placebo. naltrexone
is a drug that blocks the effects of endogenous op.... They found that after eight weeks of treatment, naltrexone
was able to reduce the urges to steal and stealing...
Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers
...d an eight-week, double-blind study of 25 men and women ages 17-75, who spent an average of at least one hour a week stealing. Those who took the drug naltrexone
(mean dose of 117mg/day) reported significantly greater decline in stealing behavior compared to those taking placebo.
The research is published in ...
Hormone Drug May Help Drinkers Stay Sober
...humans for the treatment of hyperprolactinemia."
Only three medications have FDA approval for treating alcohol dependence -- disulfiram (Antabuse), naltrexone
(Depade, ReVia), and acamprosate (Campral).
The U.S. National Institutes of Health estimates that almost 18 million people in the United States --...
UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober
...t, according to the National Institutes of Health. But there are just three medications approved to treat alcohol dependence -- disulfiram (Antabuse), naltrexone
(Depade, ReVia), and acamprosate (Campral).
Lead author of the study is Sebastien Carnicella, PhD, postdoctoral fellow at the Gallo Center. Co-aut...
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
...morphine sulfate extended-release with sequestered naltrexone
hydrochloride), both of which are designed to resi...morphine sulfate extended-release with sequestered naltrexone
ALO-01(morphine sulfate extended-release with sequestered naltrexone
hydrochloride) Capsules (EMBEDA(TM)), Alpharma's p...
Prescribed Meds Still Best Treatment for Alcoholism
...heir relapse rates appeared to be more a function of inadequate exposure to naltrexone
and less influenced by CBI," he added.
Overall, specialized CBI did not ...ion adherence rates," Zweben said.
The findings show that combing MM and naltrexone
could benefit a large percentage of alcohol-dependent patients.
Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine
... 2005 Treatment Episode Data Set (TEDS)
Evaluation of Lacosamide in Diabetic Neuropathic Pain Trials
A Pilot Study to Select a Dose of naltrexone
Hydrochloride That Will Reduce Subjective Euphoric Effects of Oxycodone Hydrochloride in Non-Dependent, Opioid-Preferring Subjects
Naltrexone in Medical Technology
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
- Improved Pharmacokinetic Characteristics of Naltrexone
SR Associated with Better Tolerability in Clinical Trials -
PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc.
(Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of
obesity and other ce...
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc.
(NYSE: ALO ), a global specialty pharmaceutical company, today announced
results from its Phase III pivotal efficacy trial that showed ALO-01
(EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ),
a global specialty pharmaceutical company, today announced results from
clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate
extended-release with sequestered naltrexone
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
...rally well tolerated.
Evaluation of Plasma naltrexone
Concentrations Resulting From Use of ALO-01 (morphine sulfate extended-release with sequestered naltrexone
hydrochloride) Capsules for Chronic Pain
EMBE...n of morphine sulfate surrounding an inner core of naltrexone
hydrochloride. EMBEDA(TM) is intended to treat mo...
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
...proof-of-concept Phase 2 trials for OREX-003
(zonisamide and olanzapine to mitigate antipsychotic-associated weight gain)
and OREX-004 (fluoxetine and naltrexone
to reduce symptoms of obsessive-
compulsive disorder) will be discontinued effective immediately. The Company
intends to maintain its intellectual pr...
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
...besity product candidate, Contrave(R),
is a combination of bupropion SR and naltrexone
in a proprietary SR
formulation that also appears to result in improved tolerability compared
to the legacy naltrexone
IR formulation. Contrave currently is being
studied in four Phase III clini...
Alpharma Presents Positive Pharmacokinetic Study Results of Its
Investigational Abuse-Deterrent, Extended-Release Opioid
...stent with a sustained-release formulation and
were similar to previous study results for KADIAN(R) (morphine
sulfate extended-release) Capsules. Most naltrexone
below the assay measurement limits. Adverse events, reported in
five subjects, were mild to moderate in intensity and resolved
Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
Association (ADA) in Chicago, IL. Contrave data can be found in
category 20B, poster number 45LB entitled, "Weight Loss with
Bupropion and naltrexone
Improves Markers of
Contrave is a proprietary fixed dose combination of bupropion SR
(sustained release) and Orexigen's novel f...
Naltrexone in Biological Technology
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
...uated the additional weight loss of Contrave (32mg naltrexone
SR/360mg bupropion SR) when added to an intensive ...profile consistent with its individual components, naltrexone
and bupropion, two drugs that have been used separ...hich utilized the immediate release formulation of naltrexone
as opposed to the proprietary SR formulation used ...
Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
...yer, M.D., M.P.H., The New York Obesity
Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y.
Title: "Combination Therapy with naltrexone
+ Bupropion Causes Significant
Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals:
A Randomized Phase 3 Study Over 56 We...
Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
...t (p<0.001). Contrave was generally well tolerated by patients, with an overall safety profile that was consistent with its individual components, naltrexone
and bupropion. The most frequently observed treatment-emergent adverse events for patients on study drug were nausea, headache, constipation and dizz...
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
...ea was 4.6%, an improvement over the 11.1% discontinuation
rate seen in the Phase 2 trial (NB-201) which utilized the immediate release
formulation of naltrexone
as opposed to the proprietary SR formulation used in
this trial. The most frequently observed treatment-emergent adverse events
for patients on study...
Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
...n patent (U.S. Patent No. 7,375,111) which was
issued by the USPTO in May 2008 and broadly covers sustained release (SR)
compositions of bupropion and naltrexone
combined in a single dosage form. The
Weber/Cowley methods patent will provide protection for Contrave through mid
"The issuance of this ...
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
...008, which covers SR compositions of bupropion and naltrexone
a single dosage form through March 202...ivity. OREX-004 is a proprietary SR formulation of naltrexone
fluoxetine. The Phase 2a clinical trial, NF- ...xone
successfully achieved key objectives (lowered naltrexone
Tmax, comparable AUC). Additionall...
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
... 11:00-11:15 a.m. MT
Poster Presentation Abstract: 585-P Title: "Relative Bioavailability of Sustained-release (SR) versus Immediate-release (IR) naltrexone
(NAL) Formulations in Healthy Obese Volunteers: Implications for Improved Tolerability?" Time: 5:30-7:30 p.m. MT
Monday, October 6 Oral Presentat...
New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
...rding to this physician panel, there are a number of factors
stymieing biopharmaceutical companies, including the lackluster commercial
performance of naltrexone
and acamprosate, a lack of clear FDA guidance on
trial design and resulting indications, the stigma associated with
alcoholism and associated corporat...
DNA Predicts Reaction to Drug That Fights Alcohol Dependence
...ing gratification from alcohol. Not only did
patients who were treated with naltrexone
and have the Asp40 gene variant
go without harmful drinking for a longer pe...al without the therapy.
Gene variant carriers of all ethnicities who took naltrexone
likely than their counterparts to have a good clinical result. Ho...